WO1991018605A1 - Method for treating alcoholism with nalmefene - Google Patents

Method for treating alcoholism with nalmefene Download PDF

Info

Publication number
WO1991018605A1
WO1991018605A1 PCT/US1991/003241 US9103241W WO9118605A1 WO 1991018605 A1 WO1991018605 A1 WO 1991018605A1 US 9103241 W US9103241 W US 9103241W WO 9118605 A1 WO9118605 A1 WO 9118605A1
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol
nalmefene
drinking
extinction
administration
Prior art date
Application number
PCT/US1991/003241
Other languages
French (fr)
Inventor
John D. Sinclair
Harry Scheinin
Risto Lammintausta
Original Assignee
Sinclair John D
Harry Scheinin
Risto Lammintausta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair John D, Harry Scheinin, Risto Lammintausta filed Critical Sinclair John D
Priority to JP3509984A priority Critical patent/JP3059213B2/en
Priority to DE69123247T priority patent/DE69123247T2/en
Priority to EP91910595A priority patent/EP0531415B1/en
Priority to RU9192016403A priority patent/RU2090190C1/en
Publication of WO1991018605A1 publication Critical patent/WO1991018605A1/en
Priority to FI925513A priority patent/FI925513A/en
Priority to LVP-93-1052A priority patent/LV10190B/en
Priority to GR960403307T priority patent/GR3022289T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse

Definitions

  • the present invention relates to a treatment for alcohol abuse in which the alcohol-drinking response is extinguished over a limited number of sessions by being emitted while reinforcement from alcohol is blocked with nal efene.
  • U.S. Patent No. 4,882,335 discloses a method for treating alcoholism in which the learned response of alcohol drinking is extinguished by being emitted while the reinforcement from alcohol in the brain is blocked with an opiate antagonist.
  • naloxone, naltrexone, cycloazocine, diprenorphine, etazocine, levalorphan, metazocine, nalorphine and salts thereof only naloxone and naltrexone are approved for general use.
  • Naloxone cannot be taken orally.
  • Naltrexone can be taken orally but because of a high first-pass metabolism, its oral availability is only 5%. Variability in first-pass metabolism also makes oral dosing with naltrexone less predictable than desired.
  • Naltrexone is also now considered to be a first-class hepatotoxin. Since alcohol abuse ' is frequently accompanied by liver damage, the use of naltrexone is counterindicated in patients with alcoholic liver cirrhosis and is questionable in other alcoholics that have not yet developed cirrhosis.
  • the present invention there is provide a therapeutic method for extinguishing the alcohol drinking response of alcoholics using the opiat antagonist nalmefene.
  • the method consists of numerou sessions in which the alcoholic takes nalmefene and the drinks, al-c ⁇ faol W-hile stafficieirfc am ⁇ mrfcs of -nalmefene ar present to block reinforcement from the alcohol.
  • Fig. 1 shows the apparent extinction of alcoho drinking in AA rats caused by four daily 1 hour session of drinking alcohol after administration of nalmefen (mean ⁇ standard error) .
  • nalmefene can be taken in capsule form, but the procedure used by Yeomans et al. (1990) of giving it in grapefruit juice, or some other non-alcoholic beverage with a slightly bitter taste, will be less obtrusive.
  • Nalmefene can be used either in a program of non- selective or selective extinction of the alcohol-drinking response.
  • nalmefene is given twice daily and the patients allowed to drink normally without supervision. Because active amounts of nalmefene are continually present during the .treatment period, all alcohol drinking occurs in the absence of reinforcement. Extinction treatment with nalmefene administration is continued until the patient's alcohol intake is reduced to a level at which withdrawal symptoms begin. Nalmefene administration is then stopped and the patient treated in the normal manner for withdrawal.
  • nalmefene is given about an hour before the beginning of an evening extinction session.
  • the patient then drinks alcohol under supervision in a manner similar to his or her normal drinking practices as determined by an earlier interview given to the patient and/or associates.
  • abstinence is strictly enforced until the next nalmefene administration the following evening, e.g., by keeping the patient in the treatment center at all times except during the extinction sessions.
  • Extinction sessions could occasionally be held in the daytime, especially for patients who previously had used alcohol frequently during the day or, early in treatment, for patients saying that they are experiencing severe craving or beginning withdrawal symptoms.
  • Non-selective extinction has the advantage of being easier to administrate and perhaps also of having the alcohol drinking occurring under more natural circumstances. Selective extinction on the other hand has
  • the duration of the extinction program can, therefore, range from about 1 to 5 weeks.
  • the final extinction sessions can be conducted with an element of punishment.
  • punishment is ineffective if positive reinforcement is still being produced by the same response, punishment may be useful while the positive reinforcement is blocked.
  • Examples of punishment include mild electric shock when alcohol is consumed, production of conditioned taste aversions from very large doses of alcohol with or without emetics, aversion therapy with an alcohol-sensitizing compound such as disulfiram or cyanamide, and the like.
  • the patient can also be informed that although his or her alcohol-drinking response has been extinguished in the most frequently used drinking situations, it is possible that some have been missed. Consequently, if the patient anticipates or is experiencing a situation in which the response has not yet been extinguished, he or she should request additional extinction sessions with nalmefene involving this new situation. This can be combined with a program of cue exposure, in which the patient is instructed first to take nalmefene and then to engage in all of the activities normally involved in alcohol drinking but refrain from actually drinking alcohol.
  • the patient succeeds in not drinking, the repeated exposure to the cues should reduce their ability to trigger alcohol drinking, but if the patient occasionally fails to .abstain, the drinking in the presence of nalmefene will constitution an additional extinction session, further weakening the alcohol-drinking response.
  • the patient can be kept on a maintenance program with continued administration of nalmefene.
  • The..-me ho according to the present invention for extinguishing alcohol drinking using nalmefene avoids the disadvantages associated with the use of naloxone and naltrexone and provides various advantages.
  • Nalmefene can be taken orally and has a 40-50% oral
  • first-pass metabolism does not vary significantly with nalmefene.
  • Oral administration of nalmefene offers the usual advantages (e.g., patient acceptability) and also an important advantage over injection specific to the extinction procedure. Namely, injection itself may act as a clear stimulus distinguishing the treatment sessions from normal drinking and thus lessening the effectiveness of extinction-
  • nalmefene is safe for human use and there is currently no evidence of side-effects or adverse reactions that would limit its use with alcoholics.
  • nalmefene The elimination half-life of nalmefene, about 8 hours in humans, is suitable for selective or non-selective extinction of alcohol drinking a described hereinbefore.
  • Nalmefene is much more potent than naloxone - 28 times more potent in precipitating withdrawal from opiate dependence in the rat as measured by a sudden rise in tail skin temperature (Katovich et al. Substances and Alcohol
  • Nalmefene is highly specific opiate antagonist without intrinsic agonistic activity, and thus with no abuse potential of its own. Subjective effects of the antagonist are minimal: e.g., a recent study on feeding (Yeomans et al., Psychopharmacology 100: 426-432, 1990) reported only a slight increase in self- rated alertness and decreases in ratings of both tiredness and elation.
  • the present invention is further illustrated by the following example which shows that nalmefene is very effective in suppressing alcohol drinking in rats, apparently through the extinction of their alcohol ⁇ drinking response and that nalmefene administered orally is also effective.
  • the AA rat line has been developed in the laboratory of Alko Ltd. , the Finnish State Alcohol Company, by selective breeding for high alcohol consumption. It is believed to be a suitable animal model for studying the effect of pharmacological treatments on alcohol drinking, and especially heavy alcohol drinking induced partially by a genetic predisposition.
  • Tlie -half-life of nalmefene in rats is about one hour and.-there is no accumulation or sequestering in specific tissues. Consequently, essentially all nalmefene from one injection would have been eliminated after 24 hours when the next injection was given, and the systemic levels should have been the same on each of the 4 treatment days.
  • the progressive . ecrease however, resembles the results in extinction studies, and is what would be expected if the alcohol-drinking response got weaker each day when it was emitted while reinforcement was blocked.
  • nalmefene was added to the food of the rats that had been the saline-injected controls in the first part of the study.
  • the amount of nalmefene was calculated on the basis of prior food intake to produce a daily intake of 18 g/kg body wt (i.e., 404 mg/kg food), an oral dose roughly equivalent to the 0.36 mg/kg dose given by injection.
  • Oral nalmefene also reduced alcohol drinking.
  • nalmefene is effective i suppressing alcohol drinking in rats, not only whe injected, but also when administered by the preferred oral route.

Abstract

A method for treating alcoholism. The alcoholdrinking response of alcoholics is extinguished by having them drink alcoholic beverages while nalmefene, an opiate antagonist, blocks the positive reinforcement effect of ethanol in the brain.

Description

METHOD FOR TREATING ALCOHOLISM WITH NALMEFENE
FIELD OF THE INVENTION
The present invention relates to a treatment for alcohol abuse in which the alcohol-drinking response is extinguished over a limited number of sessions by being emitted while reinforcement from alcohol is blocked with nal efene.
BACKGROUND OF THE INVENTION
U.S. Patent No. 4,882,335 discloses a method for treating alcoholism in which the learned response of alcohol drinking is extinguished by being emitted while the reinforcement from alcohol in the brain is blocked with an opiate antagonist.
The antagonists disclosed for use in the method described in U.S. Patent No. 4,882,335, however, have various disadvantages. Of the antagonists specifically disclosed, i.e., naloxone, naltrexone, cycloazocine, diprenorphine, etazocine, levalorphan, metazocine, nalorphine and salts thereof, only naloxone and naltrexone are approved for general use. Naloxone cannot be taken orally. Naltrexone can be taken orally but because of a high first-pass metabolism, its oral availability is only 5%. Variability in first-pass metabolism also makes oral dosing with naltrexone less predictable than desired.
Naltrexone is also now considered to be a first-class hepatotoxin. Since alcohol abuse ' is frequently accompanied by liver damage, the use of naltrexone is counterindicated in patients with alcoholic liver cirrhosis and is questionable in other alcoholics that have not yet developed cirrhosis.
It is an object of the present invention, therefore, to provide a method for treating alcoholism in which the learned response of alcohol drinking is extinguished while the reinforcement from alcohol in the brain is blocke with an opiate antagonist which avoids the disadvantage of the antagonists.previously disclosed for .suc use.
This and other objects and advantages of the presen invention are accomplished with the use of the opiat antagonist nalmefene as described hereinafter.
SUMMARY OF THE INVENTION According to the present invention there is provide a therapeutic method for extinguishing the alcohol drinking response of alcoholics using the opiat antagonist nalmefene. The method consists of numerou sessions in which the alcoholic takes nalmefene and the drinks, al-cσfaol W-hile stafficieirfc amαmrfcs of -nalmefene ar present to block reinforcement from the alcohol.
BRIEF DESCRIPTION OF THE DRAWING
Fig. 1 shows the apparent extinction of alcoho drinking in AA rats caused by four daily 1 hour session of drinking alcohol after administration of nalmefen (mean ± standard error) .
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Individuals classified as being alcoholics or alcoho abusers are screened for counterindications such Korsakoff's syndrome. Nalmefene is then given. It can given by injection, transdermal administration, nas administration, suppository, sublingual administratio and the like, but oral administration is preferre Previous studies indicate that oral doses of up to 300 can be taken without clinically relevant side-effec (Dixon et al., Clin Pharmacol 27; 233-239, 1987) . Yeoma et al- (Psychopharmacoloαv 100^ 426-432, 1990) , -howeve reported that subjects were able to distinguish nalmefe from placebo with doses of 5 g or more, but not with 2. mg. Since extraneous factors that distinguish t extinction session from normal drinking are likely reduce the effectiveness of extinction, an initial dose of approximately 2.5 mg for patients weighing about 70 kg is preferred. The nalmefene can be taken in capsule form, but the procedure used by Yeomans et al. (1990) of giving it in grapefruit juice, or some other non-alcoholic beverage with a slightly bitter taste, will be less obtrusive.
Nalmefene can be used either in a program of non- selective or selective extinction of the alcohol-drinking response. In the non-selective program, nalmefene is given twice daily and the patients allowed to drink normally without supervision. Because active amounts of nalmefene are continually present during the .treatment period, all alcohol drinking occurs in the absence of reinforcement. Extinction treatment with nalmefene administration is continued until the patient's alcohol intake is reduced to a level at which withdrawal symptoms begin. Nalmefene administration is then stopped and the patient treated in the normal manner for withdrawal. In a program of selective extinction of the alcohol¬ drinking response, typically nalmefene is given about an hour before the beginning of an evening extinction session. During the session, the patient then drinks alcohol under supervision in a manner similar to his or her normal drinking practices as determined by an earlier interview given to the patient and/or associates. After the 4-6 hour session, abstinence is strictly enforced until the next nalmefene administration the following evening, e.g., by keeping the patient in the treatment center at all times except during the extinction sessions.
Extinction sessions could occasionally be held in the daytime, especially for patients who previously had used alcohol frequently during the day or, early in treatment, for patients saying that they are experiencing severe craving or beginning withdrawal symptoms.
Non-selective extinction has the advantage of being easier to administrate and perhaps also of having the alcohol drinking occurring under more natural circumstances. Selective extinction on the other hand has
-the advantage that only the alcohol drinking response shows a net weakening over several days of treatment.
5 Other responses, such as the eating of highly palatable food, which also are reinforced through the opiate system, might be weakened somewhat during one extinction session if they happen to be emitted while high levels of xtalraefene are present. *Fhese responses, however, "will 0 regain their strength when they are emitted in the absence of nalmefene the next day and are thus again reinforced. The alcohol-drinking response, which can only be made while the reinforcement is blocked, becomes progressively weaker with each extinction session. Since, the propensity L5 - to drink alcohol i.s a unction of x-he relative strength of alcohol drinking in comparison to all competing responses, selective extinction will be more effective if competing responses are reinforced through the opiate system. Furthermore, it will preclude side-effects from weakening 0 of other responses.
Extinction of the alcohol drinking response, either selectively or non- electively, should -not fee expected to be successful alone in the treatment of alcoholism because the patient can readily relearn the response if drinking
25 is attempted after the termination of nalmefene administration. However, once the extinction has been completed, the accompanying craving for alcohol should also fee greatly reduced. Consequently-, conventional methods for increasing the motivation and incentive for
30 remaining abstinent should be sufficient to prevent relapse.
.The duration of extinction treatment required fo each patient will depend upon the severity of his or he alcoholism and the number of specific drinking situation
35 in which the alcohol-drinking response must b extinguished. The duration of the extinction program can, therefore, range from about 1 to 5 weeks.
Once the alcohol-drinking response has been sufficiently weakened, the final extinction sessions can be conducted with an element of punishment. Although punishment is ineffective if positive reinforcement is still being produced by the same response, punishment may be useful while the positive reinforcement is blocked. Examples of punishment include mild electric shock when alcohol is consumed, production of conditioned taste aversions from very large doses of alcohol with or without emetics, aversion therapy with an alcohol-sensitizing compound such as disulfiram or cyanamide, and the like.
After the final extinction session, the patient is told to abstain from all alcohol in the future. Various procedures can be used to help ensure that the patient does in fact refrain from drinking alcohol. Such procedures include counseling, psychotherapy, family therapy, job therapy, joining Alcoholics Anonymous, and the like. Efforts should also be taken to help the patient resume a normal productive life and avoid situations and other stimuli previously associated with alcohol drinking.
The patient can also be informed that although his or her alcohol-drinking response has been extinguished in the most frequently used drinking situations, it is possible that some have been missed. Consequently, if the patient anticipates or is experiencing a situation in which the response has not yet been extinguished, he or she should request additional extinction sessions with nalmefene involving this new situation. This can be combined with a program of cue exposure, in which the patient is instructed first to take nalmefene and then to engage in all of the activities normally involved in alcohol drinking but refrain from actually drinking alcohol. If the patient succeeds in not drinking, the repeated exposure to the cues should reduce their ability to trigger alcohol drinking, but if the patient occasionally fails to .abstain, the drinking in the presence of nalmefene will constitution an additional extinction session, further weakening the alcohol-drinking response. Alternatively, the patient can be kept on a maintenance program with continued administration of nalmefene.
The..-me ho according to the present invention for extinguishing alcohol drinking using nalmefene avoids the disadvantages associated with the use of naloxone and naltrexone and provides various advantages.
Nalmefene can be taken orally and has a 40-50% oral
- .availabi ity. - -Additionally, first-pass metabolism does not vary significantly with nalmefene. Oral administration of nalmefene offers the usual advantages (e.g., patient acceptability) and also an important advantage over injection specific to the extinction procedure. Namely, injection itself may act as a clear stimulus distinguishing the treatment sessions from normal drinking and thus lessening the effectiveness of extinction-
Extensive research has indicated that nalmefene is safe for human use and there is currently no evidence of side-effects or adverse reactions that would limit its use with alcoholics.
The elimination half-life of nalmefene, about 8 hours in humans, is suitable for selective or non-selective extinction of alcohol drinking a described hereinbefore.
Nalmefene is much more potent than naloxone - 28 times more potent in precipitating withdrawal from opiate dependence in the rat as measured by a sudden rise in tail skin temperature (Katovich et al. Substances and Alcohol
Actions/Misuse 5; 87-95, 1984) - and also somewhat more potent than naltrexone. Nalmefene is highly specific opiate antagonist without intrinsic agonistic activity, and thus with no abuse potential of its own. Subjective effects of the antagonist are minimal: e.g., a recent study on feeding (Yeomans et al., Psychopharmacology 100: 426-432, 1990) reported only a slight increase in self- rated alertness and decreases in ratings of both tiredness and elation.
The present invention is further illustrated by the following example which shows that nalmefene is very effective in suppressing alcohol drinking in rats, apparently through the extinction of their alcohol¬ drinking response and that nalmefene administered orally is also effective.
EXAMPLE
Extinction of alcohol drinking with nalmefene
Methods
Male rats from the F56 generation of the AA line were used. The AA rat line has been developed in the laboratory of Alko Ltd. , the Finnish State Alcohol Company, by selective breeding for high alcohol consumption. It is believed to be a suitable animal model for studying the effect of pharmacological treatments on alcohol drinking, and especially heavy alcohol drinking induced partially by a genetic predisposition.
Thirty rats were given a choice between 10% (v/v) ethanol solution and water in graduated 100 ml Richter tubes. Alcohol was continually available during the first 36 days, but thereafter for only 1 hour each day (15:30 to 16:30) . Standard rat food was always available; food jars were weighed daily approximately 20 min. before alcohol access began. Nalmefene treatment began after 85 days on alcohol (when the mean (± SE) body weight was 399 ± 9 g) , with the alcohol consumption (as g of absolute ethanol per kg body weight) during the last 4 days forming the baseline ±o∑ dividing the animals into two -matched group . One group was injected subcutaneously with 0.36 mg/kg of nalmefene (as a 0.18 mg/ml solution in normal saline) and the other group with an equivalent volume of saline on each of the next 4 days, 20 min. before access was given to alcoliol.
Results Administering nalmefene before providing access to alcohol progressively decreased alcohol drinking (Fig. 1) . The alcohol intake was significantly lower on each treatment day than the animals1 own baseline (*** p<0,OODl, **** p<0-.00001, ***** p<O. O0001) and also significantly lower than the alcohol intakes on corresponding days by the saline-injected controls (D in Fig. 1) . The alcohol intakes after the third and fourth nalmefene injections were both significantly lower than that after the first injection, i.e., on Day 86 (§ p=0.022, §§ p=0.002), illustrating the progressing decrease. This cannot be explained as a direct effect of nalmefene. Tlie -half-life of nalmefene in rats is about one hour and.-there is no accumulation or sequestering in specific tissues. Consequently, essentially all nalmefene from one injection would have been eliminated after 24 hours when the next injection was given, and the systemic levels should have been the same on each of the 4 treatment days. The progressive . ecrease, however, resembles the results in extinction studies, and is what would be expected if the alcohol-drinking response got weaker each day when it was emitted while reinforcement was blocked.
One day after the last nalmefene injection, the alcohol intake was still significantly lower than baseline (** p=0.0002) and significantly lower than that by the controls (p=0.014). Since there should have been no nalmefene left in the rats' systems at this time, the decrease cannot be attributed to a direct action of the antagonist. If- is, however, consistent with the hypothesis that the alcohol-drinking response had been progressively extinguished on the 4 preceding treatment days.
Previous operant conditioning studies have shown that alcohol is more reinforcing for AA rats than for rats of unselected strains, and that the AA rats learn alcohol- reinforced responses more rapidly. Consistent with these findings, the present AA animals rapidly relearned the alcohol-drinking response and their alcohol drinking was no longer significantly reduced on the second .day after the termination of nalmefene treatment.
There were no significant differences on any day between the nalmefene and control groups in water drinking, food intake, or body weight changes, nor any other indication of detrimental effects from nalmefene'.
Oral nalmefene Subsequently, all the rats were returned to continual access to ethanol. After their intake had stabilized, on the 115th day on alcohol, nalmefene was added to the food of the rats that had been the saline-injected controls in the first part of the study. The amount of nalmefene was calculated on the basis of prior food intake to produce a daily intake of 18 g/kg body wt (i.e., 404 mg/kg food), an oral dose roughly equivalent to the 0.36 mg/kg dose given by injection.
Oral nalmefene also reduced alcohol drinking. The alcohol intake by each of the 15 rats on nalmefene decreased, with the mean (±SE) going from 6.51 ± 0.25 g/kg during the preceding week to 4.80 ± 0.34 on the first nalmefene day (t=8.86, 14 df, p=0.0000004 relative to their own baseline; t=6.52, 28 df, p=0.0000005 relative to the 15 animals without nalmefene whose alcohol intake remained relatively constant: 6.31 ± 0.22 vs. 6.15 ± 0.28 g/kg).
The alcohol intake for the entire 4 days when nalmefene was in the food was significantly reduced
(t=12.81, 14 df, p=.000000004 relative to baseline;
Figure imgf000012_0001
relative to-controls) . At noon on
'the next day, i.e., -6 h after food intake during the active dark period should have stopped, and 6 h before it would be expected to be resumed, normal food without nalmefene was returned. During the following night, although essentially no nalmefene should have been in their systems, their alcohol drinking remained significantly suppressed (4.96 ± 0.33 g/kg; t=7.9 14 df, p=.000002, relative to baseline; t=3.55, 28 df, p=.001, relative to controls) . Subsequently, alcohol drinking returned to the pre-nalmefene baseline.
These results indicate that nalmefene is effective i suppressing alcohol drinking in rats, not only whe injected, but also when administered by the preferred oral route.

Claims

1. A method for treating alcoholism by extinguishing the alcohol-drinking response, comprising the steps of: repeatedly administering nalmefene to a subject suffering from alcoholism; while the amount of nalmefene in the subject's body is sufficient to block the stimulatory effect of alcohol, having the subject drink an alcoholic beverage; and continuing the steps of administering nalmefene and drinking an alcoholic beverage until the alcohol- drinking response is extinguished.
2. The method of claim 1 further comprising the step of punishing the patient after the alcoholic beverage is consumed, said step of punishment being selected from the group consisting of administration of electric shock, administration of emetics, and administration of an alcohol sensitizing compound.
3. 'JThe method of claim 1 further comprising continuing the administration of nalmefene after the alcohol-drinking response is extinguished.
4. The method in accordance with claim 1 wherein the dose of nalmefene is from 0.1 to 300 mg daily.
PCT/US1991/003241 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene WO1991018605A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP3509984A JP3059213B2 (en) 1990-06-04 1991-05-10 How to treat alcohol poisoning with nalmefene
DE69123247T DE69123247T2 (en) 1990-06-04 1991-05-10 METHOD FOR TREATING ALCOHOL ADDICTION WITH NALMEFEN
EP91910595A EP0531415B1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene
RU9192016403A RU2090190C1 (en) 1990-06-04 1991-05-10 Method of alcoholism treatment
FI925513A FI925513A (en) 1990-06-04 1992-12-04 FOERFARANDE FOER BEHANDLING AV ALCOHOLISM MED NALMEFEN
LVP-93-1052A LV10190B (en) 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene
GR960403307T GR3022289T3 (en) 1990-06-04 1997-01-16 Method for treating alcoholism with nalmefene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US532,424 1990-06-04
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
WO1991018605A1 true WO1991018605A1 (en) 1991-12-12

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003241 WO1991018605A1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (en)
EP (1) EP0531415B1 (en)
JP (1) JP3059213B2 (en)
AT (1) ATE145329T1 (en)
AU (1) AU642748B2 (en)
CA (1) CA2084519C (en)
DE (1) DE69123247T2 (en)
DK (1) DK0531415T3 (en)
ES (1) ES2097209T3 (en)
FI (1) FI925513A (en)
GR (1) GR3022289T3 (en)
HU (1) HU210637B (en)
IE (1) IE77333B1 (en)
LT (1) LT3893B (en)
LV (1) LV10190B (en)
NZ (1) NZ238391A (en)
RU (1) RU2090190C1 (en)
WO (1) WO1991018605A1 (en)
ZA (1) ZA914185B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789047A2 (en) * 2004-09-08 2007-05-30 Jenken Biosciences, Inc. Treatment of diseases using nalmefene and its analgos
RU2495042C2 (en) * 2008-04-24 2013-10-10 Янссен Фармацевтика Нв Nalmefene prodrugs
US8852623B2 (en) 2003-03-31 2014-10-07 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
US11642341B2 (en) 2014-04-22 2023-05-09 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
CN1204890C (en) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 Method for preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU773642C (en) 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
PT2092936E (en) 2000-02-08 2013-06-20 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP4736323B2 (en) * 2001-07-13 2011-07-27 アークレイ株式会社 Puncture element integrated body for concentration measuring device provided with analysis tool, and body fluid collection tool
DE60230632D1 (en) * 2001-07-18 2009-02-12 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
DE60232417D1 (en) 2001-08-06 2009-07-02 Euro Celtique Sa OPIOID AGONIST FORMULATIONS WITH FREEZER AND SEQUESTRATED ANTAGONIST
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
CN102813654A (en) 2002-04-05 2012-12-12 欧洲凯尔蒂克公司 Matrix for sustained, invariant and independent release of active compounds
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
ES2677769T3 (en) * 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and procedures
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
SI2484346T1 (en) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
BRPI0718420A2 (en) 2006-10-20 2013-11-12 Cpd Llc RESEARCH METHOD OF INCRETIN EFFECT
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (en) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR101598138B1 (en) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. Nalmefene di-ester prodrugs
RU2478388C2 (en) * 2008-07-07 2013-04-10 Еуро-Селтик С.А. Pharmaceutical composition, containing opioid antagonist for treatment of urinary retention
SI2405915T1 (en) 2009-03-10 2019-03-29 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. Oxycodone and naloxone combination for use in the treatment of pain in patients suffering from diseases that cause pain and intestinal dysbiosis and / or diseases that increase the risk for intestinal bacterial transfer
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
CN109069503A (en) * 2016-04-22 2018-12-21 景凯生物科技股份有限公司 The application of nalmefene (NALMEFENE), naltrexone (NALTREXONE) or derivatives thereof in treatment (non-) alcohol fatty hepatitis (NASH) or non-alcohol fatty liver (NAFLD)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
British Journal of Addiction, vol. 82, no. 11, November 1987, J.D. Sinclair: "The feasibility of effective psychopharmacological treatments for alcoholism", pages 1213-1223, see abstract; page 1216 *
British Medical Journal, vol. 297, no. 6662, 10 December 1988, J.R. Thornton et al.: "Opioid peptides and primary biliary cirrhosis", pages 1501-1504, see abstract; introduction *
Clin. Pharmacol. Ther., vol. 40, no. 5, 1986, T.J. Gal et al.: "Prolonged blockade of opioid effect with oral nalmefene", pages 537-542, see abstract *
Federation of American Societies for Experimental Biology, 68th Annual Meeting, St Louis, Missouri, 1-6 April 1984, abstract 3967, see abstract *
J. Clin. Pharmacol., vol. 27, 1987, R. Dixon et al.: "Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist", pages 233-239, see abstract (cited in the application) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852623B2 (en) 2003-03-31 2014-10-07 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US9278163B2 (en) 2003-03-31 2016-03-08 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
EP1789047A2 (en) * 2004-09-08 2007-05-30 Jenken Biosciences, Inc. Treatment of diseases using nalmefene and its analgos
EP1789047A4 (en) * 2004-09-08 2010-03-17 Jenken Biosciences Inc Treatment of diseases using nalmefene and its analgos
RU2495042C2 (en) * 2008-04-24 2013-10-10 Янссен Фармацевтика Нв Nalmefene prodrugs
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
US11642341B2 (en) 2014-04-22 2023-05-09 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Also Published As

Publication number Publication date
HUT65523A (en) 1994-06-28
EP0531415B1 (en) 1996-11-20
LV10190A (en) 1994-10-20
LV10190B (en) 1995-06-20
IE911888A1 (en) 1991-12-04
HU210637B (en) 1995-06-28
DE69123247D1 (en) 1997-01-02
CA2084519A1 (en) 1991-12-05
ES2097209T3 (en) 1997-04-01
RU2090190C1 (en) 1997-09-20
CA2084519C (en) 1999-02-09
ZA914185B (en) 1992-07-29
LTIP1486A (en) 1995-09-25
AU642748B2 (en) 1993-10-28
GR3022289T3 (en) 1997-04-30
LT3893B (en) 1996-04-25
FI925513A0 (en) 1992-12-04
AU7974091A (en) 1991-12-31
US5086058A (en) 1992-02-04
JPH06506665A (en) 1994-07-28
ATE145329T1 (en) 1996-12-15
EP0531415A1 (en) 1993-03-17
NZ238391A (en) 1997-06-24
HU9203835D0 (en) 1993-03-29
DE69123247T2 (en) 1998-01-15
JP3059213B2 (en) 2000-07-04
IE77333B1 (en) 1997-12-03
DK0531415T3 (en) 1996-12-09
FI925513A (en) 1992-12-04

Similar Documents

Publication Publication Date Title
AU642748B2 (en) Method for treating alcoholism with nalmefene
US4882335A (en) Method for treating alcohol-drinking response
Bem et al. Dextromethorphan: an overview of safety issues
Litten et al. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991
Martin-Fardon et al. Nociceptin prevents stress-induced ethanol-but not cocaine-seeking behavior in rats
Lynch et al. Biological basis of sex differences in drug abuse: preclinical and clinical studies
AU644145B2 (en) Method for treating emotional numbness
Olson et al. Endogenous opiates: 1997
Stapleton et al. Naloxone reduces fluid consumption in water-deprived and nondeprived rats
Kars et al. Naltrexone attenuates self-injurious behavior in mentally retarded subjects
DE112006001234T5 (en) Method and composition for the treatment of ARG
Froehlich et al. Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone
EP0563336B1 (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
US7910599B2 (en) Method for treating eating disorders by selective extinction with transdermal naloxone
Froehlich et al. Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism
EP1217999A2 (en) The use of baclofen in the treatment of alcoholism
US5587381A (en) Method for terminating methadone maintenance through extinction of the opiate-taking responses
AU2001218105B2 (en) Behavior chemotherapy
Bhargava Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies
Nagain‐Domaine et al. Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat
Berg et al. The relationship of alcohol drinking and endogenous opioids: the opioid compensation hypothesis
Doty et al. Effects of Naltrexone Pretreatment on Acute Responses to Ethanol in Social Drinkers
Rothman et al. Absorption and Metabolism
Hollandsworth et al. Psychoactive Substance Use Disorders
Handunge Endogenous Neuropeptide Tyr-MIF-1 Precipitates Abstinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2084519

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 925513

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1991910595

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991910595

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991910595

Country of ref document: EP